AFT hits NZ$200m milestone

FOR the first time, AFT Pharmaceuticals has surpassed NZ$200 million in revenue, achieving total sales of NZ$208 million for FY25.

The New Zealand-based company is anticipating an operating profit of NZ$20-$24 million for FY2026, putting it in a good position to achieve its revenue goal of NZ$300 million in FY27.

The robust results were boosted by AFT Pharmaceuticals’ core Australasian business, which it said “continues to be the cornerstone of our financial strength”, with Australia and New Zealand delivering combined sales of NZ$181 million.

During its annual meeting last week, the company revealed it has significantly expanded its presence in overseas markets, particularly North America, where it has launched both the intravenous and tablet form of its pain relief medicine, Maxigesic.

AFT Pharmaceuticals has a robust pipeline in the works, with eight patented products in active research and development, and 24 off-patent injectables plus an improved migraine treatment formulation progressing in several markets, including through its affiliates.

“We have established a decades-long record of driving growth, founded on our ability to identify and meet unmet clinical needs and through in-licensing products to meet that need and by developing innovative new medicines,” commented AFT Pharmaceuticals Managing Director Hartley Atkinson (pictured).

“Our R&D pipeline will play an essential role in extending this record – it opens the door to new markets, new applications, and improved outcomes for patients.

“We are confident that this pipeline, together with our established commercial platforms, positions us for sustained performance and long-term creation of shareholder value.” JM